Association of CD44 Gene Polymorphism with Survival of NSCLC and Risk of Bone Metastasis

Yaosheng Liu*  
Haifeng Qing*  
Xiuyun Su  
Cheng Wang  
Zhuo Li  
Shubin Liu

* These authors contributed equally to this work and should be considered co-first authors

Corresponding Authors: Yaosheng Liu, e-mail: yshengliubj@163.com, Shubin Liu, e-mail: sbmmsbj@163.com

Source of support: The work is supported by Application Study of Capital Clinical Characteristics of China. (No Z131107002213052)

Background: Previous studies have reported CD44 expression influenced the development and progression of tumors. The aim of this study was to investigate whether single-nucleotide polymorphisms (SNPs) of the CD44 gene are associated with survival of non-small cell lung cancer (NSCLC) and occurrence rate of bone metastasis.

Material/Methods: A total of 234 patients with NSCLC between 2003 and 2010 were enrolled in this study and 468 healthy persons were used as controls. Two polymorphisms, rs13347 and rs187115, in the CD44 gene were genotyped using DNA from blood lymphocytes. For statistical analysis we used the chi-square test, Fisher's exact test, Kaplan-Meier method, and log-rank test.

Results: CD44 gene rs13347 polymorphism was not associated with NSCLC risk. For rs187115, the association with NSCLC risk was observed (P<0.001). Allele G carriers had significantly higher occurrence rates of bone metastasis (OR=0.4, 95%CI: 0.20–0.64, P<0.001) and more advanced tumor stage (OR=2.6, 95%CI: 1.50–4.45, P=0.001) compared to carriers of allele A. The survival rates for patients with AA genotype were significantly higher than for patients with the AG+GG genotypes (P<0.001). In multivariate analysis of survival in NSCLC patients, significant predictors were CD44 gene (AG+GG) (RR=0.48, 95%CI: 0.34–0.68, P<0.001), tumor stage (RR=0.45, 95%CI: 0.31–0.65, P<0.001), and bone metastasis (RR=1.52, 95%CI: 1.05–2.21, P=0.027).

Conclusions: CD44 gene rs187115 polymorphism is a potential predictive marker of survival in NSCLC patients, and is significantly correlated with bone metastasis and tumor stage.

MeSH Keywords: Bone Diseases • Carcinoma, Non-Small-Cell Lung • Polymorphism, Single Nucleotide • Survival Analysis

Full-text PDF: http://www.medscimonit.com/abstract/index/idArt/894357
Background

Lung cancer is the most common cause of cancer-related deaths worldwide, with more than 1.6 million new cancer cases and 1.4 million deaths in the year 2008 [1]. More than 80% of patients with primary lung cancer were pathologically diagnosed with non-small cell lung cancer (NSCLC) [2,3]. Approximately 55% of patients with NSCLC suffer from distant metastases [4], including to bone, liver, lung, and brain. Bone is the most common site for distant metastasis in NSCLC patients [5]. It has been reported that 30–65% of patients with NSCLC will develop bone metastases [6], with a median survival of less than 8 months [7,8]. Bone metastases can result in significant morbidity and severely decreased quality of life [9–11] due to various skeletal complications such as pathological fractures, serious bone pain, spinal cord compression, and hypercalcemia [6,12,13].

To date, the exact molecular and cellular mechanisms of the development of NSCLC and bone metastasis in NSCLC are still unclear. Many studies [14–17] have recently reported that genes, including osteopontin, CCR2-64I, XRCC1, and IL-1β gene, may play roles in the emergence and progression of NSCLC.

As the most common type of DNA sequence variation, single-nucleotide polymorphisms (SNPs), may affect the expression of certain genes [33,34]. Previous studies have reported that SNPs rs13347 and rs187115 in CD44 gene were significantly associated with the risk of human tumors [32,35–37]. However, few studies have investigated the association of CD44 polymorphisms with survival of NSCLC and risk of bone metastasis. Therefore, we conducted the present study to investigate whether the 2 SNPs (rs13347 and rs187115) in the CD44 gene have roles on the survival of patients with NSCLC and to explore whether they are associated with incidence of bone metastasis development.

Material and Methods

This study was approved by the ethics committee of the 307th PLA Hospital. Written informed consent was obtained from all enrolled participants. In this study, we recruited a total of 234 patients (156 males and 78 females) diagnosed with NSCLC between July 2003 and September 2010, 65 of which had bone metastasis and the remaining 169 were without bone metastasis. Matched-control subjects were 468 unrelated healthy individuals (308 males and 160 females) during the same period, based on sex and age. The TNM stage of the patients and differentiation system were determined according to International Association of Lung Cancer [38]. The characteristics of the patients from medical records, including age, sex, pathological tumor stage, histopathological diagnosis, and the follow-up, are displayed in Table 1. Individuals with abnormal test results were excluded from the matched-control group. All patients in this study were assessed for bone metastasis according to methods described in a previous study [14]. Blood samples were collected for genomic DNA extraction from patients and healthy controls in Vacutainer tubes containing heparin as an anticoagulant.

DNA extraction and SNP genotyping analysis

Genomic DNA was prepared using the QIAamp DNA mini Kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. DNA samples were stored at −20°C until genotypic analysis was performed. SNP rs13347 and rs187115 in CD44 gene were genotyped using the Taqman allelic discrimination method (Applied Biosystems, Foster City, CA, USA) [39]. The PRIMER sequences were previously described [36]. The TaqMan assays were conducted in a final reaction volume of 5 ml containing 0.25 ml primer, 0.125 ml probe, 2 ml PCR mixture reagent, and 25 ng DNA. The polymerase chain reaction (PCR) consisted of an initial step at 95°C for 10 min followed by 55 cycles of denaturing at 95°C for 15 s and annealing at 60°C for 1 min [36,40]. Allelic discrimination software was used to analyze the PCR genotyping results.

Statistical analysis

All statistical analyses were performed using SPSS19.0 software (SPSS Company, Chicago, IL). Hardy-Weinberg equilibrium (HWE) was evaluated using a χ²-test. The differences in distributions of the variables between patients and healthy controls were evaluated by Mann-Whitney U test and Fisher’s exact test. The comparison of allele type and genotype distributions in the patients and healthy controls was assessed by computing the odds ratio (OR) and 95% confidence intervals (95% CI) from logistic regression analyses. Survival was calculated from the date of surgery to the time of death using the Kaplan-Meier method. P values less than 0.05 were considered significant for all statistical analyses.
Results

Patient clinical characteristics

Among a total of 702 subjects of this study, the mean age was 62.21±9.8 years in cases and 61.87±10.75 in matched-pair controls. There were no significant differences in mean age and sex distributions between cases and controls. Distribution of genotypes of the 2 polymorphisms in healthy control group was in accordance with Hardy-Weinberg equilibrium in our study. Of the 234 NSCLC patients, 65 (28%) were diagnosed with bone metastasis. The follow-up period ranged from 23 to 117 months (median, 60 months; mean, 71 months). Among the 234 patients, 171 patients survived less than 5 years and 63 patients survived over 5 years (5-year survival rate of 27%). Characteristics of NSCLC patients and age- and sex-matched controls are shown in Table 1.

CD44 gene Polymorphisms with NSCLC

Table 2 shows the association of each of the SNPs in CD44 gene with the risk of NSCLC. There were no significant differences in the genotypic and allelic distributions of rs13347 polymorphisms between NSCLC patients and healthy controls. However, significant differences were observed in the relationship between frequency distributions of rs187115 and the NSCLC risk. Allele G of rs187115 SNP significantly increased NSCLC risk.

As shown in Table 3, further analysis based on stratification of clinicopathological features revealed significant correlations of frequency distributions of rs187115 SNP with NSCLC risk in tumor stage (OR=2.6, 95%CI: 1.50–4.45, P=0.001) and bone metastasis (OR=0.4, 95%CI: 0.20–0.64, P<0.001). By comparing with AA genotype, the results indicated that genotype of AG plus GG at rs187115 might significantly increase presence of advanced stage and the risk of development of bone metastasis.

CD44 gene polymorphisms with NSCLC prognosis

Patient survival analysis showed a clear positive correlation between different genotypes at rs187115 in CD44 gene (P<0.001, log-rank=25.999) (Figure 1). The survival rates for patients with the AA genotype were significantly higher than for patients with the AG+GG genotypes (P<0.001). Then, we carried out Cox regression analysis. After the univariate analysis, we found that the genotype of rs187115 and 2 clinicopathological parameters – tumor stage and bone metastasis – might be associated with the prognosis of NSCLC (Table 4). Further analyses of all variables in multivariate analysis subsequently revealed that CD44 gene (AG+GG) (RR=0.48, 95%CI: 0.34–0.68, P<0.001), tumor stage (RR=0.45, 95%CI: 0.31–0.65, P<0.001), and bone metastasis (RR=1.52, 95%CI: 1.05–2.21, P=0.027) might also be independent prognostic factors for NSCLC (Table 4).
Table 2. Distribution frequency of clinicopathological features and CD44 rs187115 genotype frequencies in 234 patients with NSCLC.

| Variable | Cases (n=234) | Controls (n=468) | OR (95% CI) | P-value |
|----------|---------------|------------------|-------------|---------|
| rs13347  |               |                  |             |         |
| CC       | 179           | 337              | 1 (Reference) | –       |
| CT       | 51            | 121              | 1.3 (0.87–1.83) | 0.225   |
| TT       | 4             | 10               | 1.3 (0.41–4.29) | 0.635   |
| CT+TT    | 55            | 131              | 1.3 (0.88–1.82) | 0.204   |
| rs187115 |               |                  |             |         |
| AA       | 133           | 336              | 1 (Reference) | –       |
| AG       | 86            | 119              | 0.5 (0.39–0.77) | 0.001   |
| GG       | 15            | 13               | 0.3 (0.16–0.74) | 0.005   |
| AG+GG    | 101           | 132              | 0.5 (0.37–0.72) | <0.001  |
| A        | 352           | 791              | 1 (Reference) | –       |
| G        | 116           | 145              | 0.6 (0.42–0.73) | <0.001  |

* P-value<0.05 as statistically significant.

Table 3. Distribution frequency of clinicopathological features and CD44 rs187115 genotype frequencies in 234 patients with NSCLC.

| Variables               | Genotypic frequencies | OR (95% CI) |
|-------------------------|------------------------|-------------|
|                         | AA (n=133)             | AG+GG (n=101)|     |
| Age, y                  |                        |             |     |
| ≥60/<60                 | 74/59                  | 58/43       | 0.9 (0.55–1.57) |
| Gender                  |                        |             |     |
| Male/female             | 89/44                  | 67/34       | 1.0 (0.59–1.78) |
| Pathological type       |                        |             |     |
| Squamous/non-squamous   | 82/51                  | 65/36       | 0.9 (0.52–1.52) |
| Tumor stage             |                        |             |     |
| I + II                  | 71                     | 31          | 0.001 |
| III + IV                | 62                     | 70          | 2.6 (1.50–4.45)* |
| Lymph node              |                        |             |     |
| Positive/negative       | 76/57                  | 68/33       | 0.6 (0.38–1.11) |
| Bone metastasis         |                        |             |     |
| Yes/no                  | 25/108                 | 40/61       | 0.4 (0.20–0.64)* |
| KPS                     |                        |             |     |
| ≥80/80                  | 96/37                  | 80/21       | 0.7 (0.37–1.26) |

* P-value<0.05 as statistically significant.
In the present study, we showed the effects of CD44 on prognosis of NSCLC and the risk of development of bone metastasis. To the best of our knowledge, this is the first investigation to report an association between CD44 polymorphisms and bone metastasis among NSCLC patients. The results in this study revealed that CD44 gene rs187115 polymorphism is a potential predictive marker of survival in NSCLC patients, and is significantly associated with bone metastasis and tumor stage.

NSCLC is a common tumor with poor prognosis. Many studies [12,41,42] have investigated the role of genetic factors in the progression and prognosis of NSCLC. A large body of evidence [25–28] suggests that CD44 gene participates in the regulation of tumor metastasis and that overexpression of CD44 is particularly observed in metastatic tumors, especially in those cancers that have a high propensity for the development of bone metastases [37,43,44]. Moreover, the overexpression of CD44 in the primary tumor is reportedly associated with early metastasis and poor prognosis in human cancers [26,37,43–45].

Table 4. Prognostic factors in Cox proportional hazards model.

| Variables          | Univariate analysis | Multivariate analysis |
|--------------------|---------------------|-----------------------|
|                    | Risk ratio | 95% CI | P-value | Risk ratio | 95% CI | P-value |
| Age, y             |            |        |         |            |        |         |
| >60/<60            | 1.024      | 0.712–1.579 | 0.703   | 1.035      | 0.686–1.561 | 0.871 |
| Gender             |            |        |         |            |        |         |
| Male/female        | 1.603      | 0.894–2.797 | 0.136   | 1.591      | 0.902–2.806 | 0.108 |
| Pathological type  |            |        |         |            |        |         |
| Squamous           | 0.619      | 0.327–1.198 | 0.172   | 0.639      | 0.339–1.204 | 0.166 |
| Non-squamous       |            |        |         |            |        |         |
| Tumor stage        |            |        |         |            |        |         |
| I + II             | 0.405      | 0.268–0.611 | <0.001* | 0.450      | 0.311–0.651 | <0.001* |
| III + IV           |            |        |         |            |        |         |
| Lymph node         |            |        |         |            |        |         |
| Positive/negative  | 0.876      | 0.487–1.564 | 0.648   | 0.885      | 0.498–1.575 | 0.679 |
| Bone metastasis    |            |        |         |            |        |         |
| Yes/no             | 1.633      | 1.064–2.504 | 0.025*  | 1.521      | 1.048–2.206 | 0.027* |
| KPS                |            |        |         |            |        |         |
| ≥80/<80            | 1.202      | 0.591–2.392 | 0.531   | 1.241      | 0.618–2.489 | 0.544 |
| Genotype           |            |        |         |            |        |         |
| AA                 | 0.459      | 0.322–0.655 | <0.001* | 0.479      | 0.337–0.680 | <0.001* |
| AG+GG              |            |        |         |            |        |         |

* P-value<0.05 as statistically significant.
It has been reported that CD44 is a cofactor with tumor promotion and tumor suppression [46,47]. It can enhance the affinity of growth factors to their authentic receptors; therefore, CD44 might play roles in proliferation and invasiveness of cells. In contrast, in other situations CD44 acts as tumor suppressor by binding to alternative ligands, resulting in growth arrest due to contact inhibition [43]. The roles of CD44 in a given cell will depend on the subtype of CD44, cellular nature of the ECM, and other unknown conditions [46].

In the current study, we found that the distribution of genotype in the CD44 gene showed significant differences between patients with and without bone metastasis, but we found no significant difference between positive and negative lymph node metastasis (Table 3). A study by Ramasami et al. [48] also showed CD44 had no significant association with lymph node metastases or tumor stage. However, Ko et al. [22] found a strong association between CD44 gene and advanced lymph node metastasis. CD44 has unconfirmed roles in metastases in patients with tumors, and further study is needed to investigate this.

Previous studies have reported varied relationships of CD44 in cancer susceptibility and prognosis. Vazquez et al. [49] reported that allele G of CD44 (rs187115) was associated with increased risk for tumor-related death and lower drug sensitivity. Jiang et al. [50] CD44 rs13347 C>T found that polymorphism may affect breast cancer development and prognosis by increasing CD44 expression. Xiao et al. [44] also found that CT and TT genotypes of rs13347 in CD44 gene were associated with increased risk of nasopharyngeal carcinoma. However, Tulsyan et al. [37] did not observe any significant differences in the frequency distribution of the genetic variants CD44 rs13347 between cases and healthy controls. In our study, we found that rs187115 was associated with NSCLC; however, the relationship between rs13347 and NSCLC was not observed. Allelic G carrier has an increased risk of NSCLC and achieves a poor prognosis. Moreover, rs187115 polymorphism is significantly correlated with bone metastasis and tumor stage. SNP rs187115 might become a potential prognostic marker for NSCLC patients.

Some limitations in this study design must be noted. First, selection bias may have occurred because the cases were enrolled from hospital but the healthy controls were chosen from the community. Second, the small sample size may cause significant fluctuations in statistics. Finally, replication in another group was not carried out.

Conclusions

In summary, our study indicated that CD44 rs187115 variant genotypes (AG + GG) could increase the risk of NSCLC and decrease survival time compared with AA genotype, and rs187115 was correlated with bone metastasis and tumor stage. However, well-designed, population-based, case-control studies with larger sample sizes are required to confirm these results.

Competing interests

The authors declare that they have no competing interests.

References:

1. Ferlay J, Shin HR, Bray F et al: Estimates of worldwide burden of cancer in 2008. GLOBOCAN 2008. Int J Cancer, 2010; 127(12): 2893–917
2. Bi N, Yang M, Zhang L et al: Cyclooxygenase-2 genetic variants are associated with survival in unresectable locally advanced non-small cell lung cancer. Clin Cancer Res, 2010; 16(8): 2383–90
3. Gandara D, Narayan S, Lara PN Jr et al: Integration of novel therapeutics by binding to alternative ligands, resulting in growth arrest due to contact inhibition. J Thorac Oncol, 2011; 6(3): 576–82
4. Tsuya A, Kurata T, Tamura K, Fukuoka M: Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer, 2007; 57(2): 219–32
5. Kozloff W, Guise TA: Breast cancer metastasis to bone: mechanisms of osteolyis and implications for therapy. J Mammmary Gland Biol Neoplasia, 2005; 10(2): 169-80
6. Coleman RE: Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res, 2006; 12(20 Pt 2): 6243s–49s.
7. Decroisette C, Mommet I, Berard H et al: Epidemiology and treatment costs of bone metastases from lung cancer: a French prospective, observational, multicenter study (GFPC 0601). J Thorac Oncol, 2011; 6(3): 576–82
8. 10. Di Maio M, Gridelli C, Gallo C et al: Prevalence and management of pain in Italian patients with advanced non-small-cell lung cancer. Br J Cancer, 2004; 90(12): 2288–96
9. Cetin K, Christiansen CF, Jacobsen JB et al: Bone metastasis, skeletal-related events, and mortality in lung cancer patients: a Danish population-based cohort study. Lung Cancer, 2014; 86(2): 247–54
10. Liu L, Chen X, Wang Y et al: Notch3 is important for TGF-beta-induced epithelial-mesenchymal transition in non-small cell lung cancer bone metastasis by regulating ZEB-1. Cancer Gene Ther, 2014; 21(9): 364–72
11. Pockett RD, Castellano D, McEwan P et al: The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain. Eur J Cancer Care (Engl), 2010; 19(6): 755–60
12. Chen Y, Liu H, Wu W et al: Osteopontin genetic variants are associated with overall survival in advanced non-small-cell lung cancer patients and bone metastasis. J Exp Clin Cancer Res, 2013; 32: 45
13. Rafrafi A, Kaabachi S, Kaabachi W et al: CCR2-64I polymorphism is associated with non-small cell lung cancer in Tunisian patients. Hum Immunol, 2015; 76(5): 348–54
14. Bhat IA, Naykoo NA, Qasim I et al: Association of interleukin 1 beta (IL-1beta) polymorphism with mRNA expression and risk of non small cell lung cancer. Meta Gene, 2014; 2: 123–33
15. Gereedil C, Artac M, Yildirim S et al: Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer. Tumour Biol, 2015 [Epub ahead of print]
18. Goodfellow PN, Banting G, Wiles MV et al: The gene, MIC4, which controls expression of the antigen defined by monoclonal antibody F10.44.2, is on human chromosome 11. Eur J Immunol, 1982; 12(8): 659–63.

19. Bourguignon LY, Zhu D, Zhu H: CD44 isozyme-cytoskeleton interaction in oncogenic signaling and tumor progression. Front Biosci, 1998; 3: d637–49.

20. Raff A, Nagarikatti M, Nagarikatti PS: Hyaluronate-CD44 interactions can induce murine B-cell activation. Blood, 1997; 89(8): 2901–8.

21. Chen D, McKallip RJ, Zeyun A et al: CD44-deficient mice exhibit enhanced hepatitis after concanavalin A injection: evidence for involvement of CD44 in activation-induced cell death. J Immunol, 2001; 166(10): 5889–97.

22. Ko YH, Won HS, Jeon EK et al: Prognostic significance of CD44s expression in resected non-small cell lung cancer. BMC Cancer, 2011; 11: 340.

23. Arch R, Wirth K, Hofmann M et al: Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science, 1992; 257(5070): 682–85.

24. Marhaba R, Zoller M: CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol, 2004; 35(3): 211–31.

25. Hill A, McFarlane S, Johnston PG, Waugh DJ: The emerging role of CD44 in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression. J Clin Invest, 2011; 121(3): 1064–74.

26. Brown RL, Reinke LM, Damerow MS et al: CD44 splice isoform switching in.

27. Luo Z, Wu RR, Lv L et al: Prognostic value of CD44 expression in non-small cell lung cancer: a systematic review. Int J Clin Exp Pathol, 2014; 7(7): 3632–46.

28. Clarke MR, Landreneau RJ, Resnick NM et al: Prognostic significance of CD44 expression in adenocarcinoma of the lung. Clin Mol Pathol, 1995; 48(4): M200–4.

29. Bertaux-Skeirik N, Feng R, Schumacher MA et al: CD44 plays a functional role in Helicobacter pylori-induced epithelial cell proliferation. PLoS Pathog, 2015; 11(2): e1004663.

30. Dong C, Ye DX, Zhang WB, Pan HY et al: Overexpression of c-fos promotes cell invasion and migration via CD44 pathway in oral squamous cell carcinoma. J Oral Pathol Med, 2015; 44(5): 353–60.

31. Zhao S, He JL, Qiu ZX et al: Prognostic value of CD44 variant exon 6 expression in non-small cell lung cancer: a meta-analysis. Asian Pac J Cancer Prev, 2014; 15(16): 6761–66.

32. Quan YH, Kim B, Park JH et al: Highly sensitive and selective anticancer effect of conjugated HA-cisplatin in non-small cell lung cancer overexpressed with CD44. Exp Lung Res, 2014; 40(10): 475–84.

33. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, Gottesman MM: Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res, 2007; 67(20): 9609–12.

34. Morley M, Molony CM, Weber TM et al: Genetic analysis of genome-wide variation in human gene expression. Nature, 2004; 430(7001): 743–47.

35. Chou YE, Hsieh MI, Chou HL et al: CD44 gene polymorphisms on hepatocellular carcinoma susceptibility and clinicopathologic features. Biomed Res Int, 2014; 2014: 213474.

36. Chou YE, Hsieh MI, Hsin CH et al: CD44 gene polymorphisms and environmental factors on oral cancer susceptibility in Taiwan. PLoS One, 2014; 9(4): e93692.

37. Tulsyan S, Agarwal G, Lal P et al: CD44 gene polymorphisms in breast cancer risk and prognosis: a study in North Indian population. PLoS One, 2013; 8(8): e71073.

38. Ahuja V, Coleman RE, Herrdon J, Patz EF Jr: The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer, 1998; 83(5): 918–24.

39. Livak KJ: Allelic discrimination using fluorogenic probes and the 5′ nuclelease assay. Genet Anal, 1999; 14(5–6): 143–49.

40. Huang SM, Cheung CW, Chang CS et al: Phloroglucinol derivative MCPF induces cell apoptosis in human colon cancer. J Cell Biochem, 2011; 112(2): 643–52.

41. Song Z, Zhang Y: Zoledronic acid treatment in advanced non-small cell lung cancer patients with bone metastases. Med Oncol, 2014; 31(4): 898.

42. Deberne M, Ropert S, Billemont B et al: Inaugural bone metastases in non-small cell lung cancer: a specific prognostic entity? BMC Cancer, 2014; 14: 416.

43. Sharma KL, Yadav A, Gupta A et al: Association of genetic variants of cancer stem cell gene CD44 haplotypes with gallbladder cancer susceptibility in North Indian population. Tumour Biol, 2014; 35(3): 2583–89.

44. Xiao M, Hu S, Zhang L et al: Polymorphisms of CD44 gene and nasopharyngeal carcinoma susceptibility in a Chinese population. Mutagenesis, 2013; 28(5): 577–82.

45. Taira N, Kawabata T, Ichikawa T et al: Long-term survival after surgical treatment of metachronous bilateral adenral metastases of non-small cell lung carcinoma. Am J Case Rep, 2014; 15: 444–46.

46. Herrlich P, Morrisson H, Sleeman J et al: CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann NY Acad Sci, 2000; 910: 106–18

47. Kanaji N, Tadokoro A, Watanabe N et al: Increases in serum CYFRA21-1 concentration during successful treatment with crizotinib. Am J Case Rep, 2014; 15: 480–84.

48. Ramasami S, Kerr KM, Chapman AD et al: Expression of CD44v6 but not E-cadherin or beta-catenin influences prognosis in primary pulmonary adenocarcinoma. J Pathol, 2000; 192(4): 427–32.

49. Vazquez A, Grochola LF, Bond EE et al: Chemosensitivity profiles identify polymorphisms in the p53 network genes 14-3-3tau and CD44 that affect sarcoma incidence and survival. Cancer Res, 2010; 70(1): 172–80.

50. Jiang L, Deng J, Zhu X et al: CD44 rs13347 C>T polymorphism predicts breast cancer risk and prognosis in Chinese populations. Breast Cancer Res, 2012; 14(4): R105